Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
Morgan Stanley 20th Annual Global Healthcare Conference
Fireside Chat: Monday, September 12, 2022 at 4:50 pm ET
Location: Sheraton Hotel, New York, NY
H.C. Wainwright 24th Annual Global Investment Conference (Hybrid)
Fireside chat: Wednesday, September 14, 2022 at 8:30 am ET
Location: Lotte New York Palace Hotel, New York, NY
Baird’s 2022 Global Healthcare Conference
Fireside chat: Wednesday, September 14, 2022 at 10:50 am ET
Location: Intercontinental New York Barclay, New York, NY
Jefferies Cell and Genetic Medicine Summit
Fireside chat: Friday, September 30, 2022
Location: Lotte New York Palace Hotel, New York, NY
A live webcast and archived replay of the fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference will be available on the investors section of www.vorbio.com.
About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.
Contact:
Media & Investors
Sarah Spencer
+1 857-242-6076
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$2.23 |
| Daily Change: | 0.02 1.00 |
| Daily Volume: | 1,844,054 |
| Market Cap: | US$278.910M |
July 21, 2025 June 25, 2025 June 25, 2025 March 20, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
